{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T20:40:01Z","timestamp":1759178401567,"version":"3.37.3"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1124\/dmd.104.001032","type":"journal-article","created":{"date-parts":[[2004,12,23]],"date-time":"2004-12-23T01:25:41Z","timestamp":1103765141000},"page":"381-387","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["RELATIONSHIPS AMONG PLASMA [2-13C]URACIL CONCENTRATIONS, BREATH 13CO2 EXPIRATION, AND DIHYDROPYRIMIDINE DEHYDROGENASE (DPD) ACTIVITY IN THE LIVER IN NORMAL AND DPD-DEFICIENT DOGS"],"prefix":"10.1016","volume":"33","author":[{"given":"Makoto","family":"Inada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Hirao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihisa","family":"Koga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Itose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-ichi","family":"Kunizaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takefumi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.104.001032_bib1","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1600-0773.1980.tb02463.x","article-title":"Pharmacokinetic studies of 5-fluorouracil after oral and intravenous administration in man.","volume":"46","author":"Almersjo","year":"1980","journal-title":"Acta Pharmacol Toxicol (Copenh)"},{"key":"10.1124\/dmd.104.001032_bib2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00008571-200004000-00002","article-title":"Known variant DPYD alleles do not explain DPD deficiency in cancer patients.","volume":"10","author":"Collie-Duguid","year":"2000","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.104.001032_bib3","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/BF00434346","article-title":"Pharmacokinetics of 5-fluorouracil infusions in the rat: comparison with man and other species.","volume":"14","author":"Collins","year":"1985","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.104.001032_bib4","first-page":"1094","article-title":"Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice.","volume":"46","author":"Desgranges","year":"1986","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.104.001032_bib5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00003088-198916040-00002","article-title":"Clinical pharmacology of 5-fluorouracil.","volume":"16","author":"Diasio","year":"1989","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.104.001032_bib6","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1021\/ja01573a087","article-title":"The synthesis of 5-fluoropyrimidines.","volume":"79","author":"Duschinsky","year":"1957","journal-title":"JAm Chem Soc"},{"key":"10.1124\/dmd.104.001032_bib7","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.1995.13.7.1663","article-title":"Response to fluorouracil therapy in cancer patients: role of tumoral dihydropyrimidine dehydrogenase.","volume":"13","author":"Etienne","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.104.001032_bib8","first-page":"2899","article-title":"Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients.","volume":"52","author":"Fleming","year":"1992","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.104.001032_bib9","first-page":"2203","article-title":"Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile.","volume":"47","author":"Heggie","year":"1987","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.104.001032_bib10","first-page":"781","article-title":"Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate.","volume":"6","author":"Ho","year":"1986","journal-title":"Anticancer Res"},{"key":"10.1124\/dmd.104.001032_bib11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0378-4347(97)00253-3","article-title":"Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity.","volume":"696","author":"Johnson","year":"1997","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"10.1124\/dmd.104.001032_bib12","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s002800050566","article-title":"Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans.","volume":"39","author":"Khor","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.104.001032_bib13","first-page":"4724","article-title":"Regional pharmacokinetics of 5-bromo-2\u2032-deoxyuridine and 5-fluorouracil in dogs: hepatic arterial versus portal venous infusions.","volume":"56","author":"Kuan","year":"1996","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.104.001032_bib14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3109\/07357909309024846","article-title":"Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity.","volume":"11","author":"Lyss","year":"1993","journal-title":"Cancer Investig"},{"key":"10.1124\/dmd.104.001032_bib15","first-page":"83","article-title":"Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.","volume":"24","author":"Morrison","year":"1997","journal-title":"Oncol Nurs Forum"},{"key":"10.1124\/dmd.104.001032_bib16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00008571-199702000-00005","article-title":"Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil.","volume":"7","author":"Nakayama","year":"1997","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.104.001032_bib17","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0026-895X(24)26498-1","article-title":"Mechanism-based inactivation of human dihydropyrimidine dehydrogenase by (E)-5-(2-bromovinyl)uracil in the presence of NADPH.","volume":"57","author":"Nishiyama","year":"2000","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.104.001032_bib18","first-page":"270","article-title":"Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.","volume":"25","author":"Okuda","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.104.001032_bib19","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0022-3565(24)37858-9","article-title":"A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.","volume":"287","author":"Okuda","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.104.001032_bib20","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1200\/JCO.1988.6.10.1653","article-title":"Fluorouracil: biochemistry and pharmacology.","volume":"6","author":"Pinedo","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.104.001032_bib21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1365-2125.1998.00751.x","article-title":"Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects.","volume":"46","author":"Ridge","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.104.001032_bib22","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1248\/bpb.20.1313","article-title":"Simultaneous evaluation of intestinal absorption and hepatic extraction of 5-fluorouracil using portal-systemic concentration difference by short-period double dosing in a single conscious rat.","volume":"20","author":"Sawai","year":"1997","journal-title":"Biol Pharm Bull"},{"key":"10.1124\/dmd.104.001032_bib23","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S0022-3565(25)30360-5","article-title":"Effects of route of administration and blood flow on hepatic drug elimination.","volume":"195","author":"Shand","year":"1975","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.104.001032_bib24","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1159\/000028209","article-title":"Liver dihydropyrimidine dehydrogenase activity in human, cynomolgus monkey, rhesus monkey, dog, rat and mouse.","volume":"56","author":"Sludden","year":"1998","journal-title":"Pharmacology"},{"key":"10.1124\/dmd.104.001032_bib25","first-page":"477","article-title":"Possible prediction of adverse reactions to fluorouracil by the measurement of urinary dihydrothymine and thymine.","volume":"2","author":"Sumi","year":"1998","journal-title":"Int J Mol Med"},{"key":"10.1124\/dmd.104.001032_bib26","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0378-4347(95)00228-B","article-title":"Automated screening system for purine and pyrimidine metabolism disorders using high-performance liquid chromatography.","volume":"672","author":"Sumi","year":"1995","journal-title":"J Chromatogr B Biomed Appl"},{"key":"10.1124\/dmd.104.001032_bib27","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/1097-0142(19800315)45:5+<1135::AID-CNCR2820451318>3.0.CO;2-Q","article-title":"Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacologic evaluation.","volume":"45","author":"Woodcock","year":"1980","journal-title":"Cancer"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624031234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624031234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.104.001032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T17:09:11Z","timestamp":1739898551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624031234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S0090955624031234"],"URL":"https:\/\/doi.org\/10.1124\/dmd.104.001032","relation":{},"ISSN":["0090-9556"],"issn-type":[{"type":"print","value":"0090-9556"}],"subject":[],"published":{"date-parts":[[2005,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RELATIONSHIPS AMONG PLASMA [2-13C]URACIL CONCENTRATIONS, BREATH 13CO2 EXPIRATION, AND DIHYDROPYRIMIDINE DEHYDROGENASE (DPD) ACTIVITY IN THE LIVER IN NORMAL AND DPD-DEFICIENT DOGS","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.104.001032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2005 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}